Improved healing of large wounds via the reprogramming of wound-resident mesenchymal cells into epithelial cells

Re-epithelialization is a key process in wound healing. However, this is insufficient to heal large wounds, such as ulcers and burns, and often skin grafts are employed.

The authors of this paper attempted to convert non-epithelial cells, which would be resident in these large wounds, to keratinocytes as a method of improving wound healing.

Comparison of the transcriptional profile of keratinocytes and dermal fibroblasts revealed 55 transcriptional factors and 31 microRNAs involved in keratinocyte specification. Various combinations were assessed for re-programming by transducing into dermal fibroblasts and monitoring conversion into keratinocytes in vitro. Four key genes were identified: DNP63A, GRHL2, TFAP2A and MYC (DGTM).

Ulcers were created in vivo and isolated using skin chambers to prevent migration of host keratinocytes and wound healing by contraction. Adenoviral delivery of DGTM genes resulted in epithelial-like tissue inside the chamber within 18 days, which resembled the skin adjacent to the wound by 28 days. Once the chamber was removed, the generated tissue then connected with the host tissue whilst maintaining a stratified structure. Further histological analysis revealed the DGTM-skin had intact barrier function, a cornified envelope and normal expression of keratins and loricrin.

Re- epithelialization was also observed when the DGTM-generated skin was wounded for a second time, and DGTM transduction promoted healing of old wounds (7 days post-wounding).

Efficiency of the transduction and conversion into keratinocytes was improved by delivery of the viruses in a collagen gel with FGF2 and a Rock inhibitor, with complete re-epithelialization within 2 – 2.5 weeks.

Although possible clinical applications of these methods are more than likely to be far into the future, they do offer an initial proof of principle for this technique in improving wound healing of skin and potentially other tissues.

Get in touch

Find out how Epistem can assist with your research…

Thank you

We will be in touch as soon as possible.

Epistem's Wound Healing Models

Epistem has validated in vivo wound healing models. These include excisional and incisional wounds, wounding of human skin engrafts, diabetic and LPS-induced inflammation wound healing models. In vitro wound healing assays are also available to assess cell proliferation/migration, wound closure and angiogenesis. We also offer gene expression profiling and biomarker identification and validation services to support all of our in vitro and in vivo models. We have recently taken delivery of a NextSeq 550 NGS machine to add more depth to our current transcriptomic services.

Kurita, M., et al. (2018). “In vivo reprogramming of wound-resident cells generate skin epithelial tissue.” Nature 561 (243-270)

About Epistem

Epistem's contract research service is committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline.

Tel: +44 (0)161 850 7600  Email: